

## **3RD EXPRESSION OF INTEREST (EOI) FOR MEDICAL PRODUCTS FOR THE ECOWAS JOINT ASSESSMENT PROCEDURE UNDER THE WEST AFRICA MEDICINES REGULATORY HARMONIZATION (WA-MRH)**

**Reference:** 019E0F503BE3

**Name:** 3rd Expression of Interest (EOI) for Medical Products for the ECOWAS Joint Assessment Procedure under the West Africa Medicines Regulatory Harmonization (WA-MRH)

### **Description:**

**Submit all dossier to lead coordinating agency (NAFDAC) as indicated in the procedure.**

### **Notice:**

This is to announce the 3rd Expression of Interest (EOI) for Medical Products for the ECOWAS Joint Assessment Procedure under the West Africa Medicines Regulatory Harmonization (WA-MRH) initiative.

1. The WA-MRH secretariat would launch an EOI for products eligible for joint evaluation listed in the EOIs for four submission windows each year, starting this October, 2021. Each window will be open for a one (1) month period in each of the four (4) quarters of the year. The months for the four windows shall be February, May, July, and October.
2. Published are EOIs to cover nine (9) therapeutic areas.
  - a. Antimalarial Medicines
  - b. Vaccines, Immunoglobulins, Well Characterized Biologics, Bio-Similar and Blood Products
  - c. Antibacterial Infections and Related Diseases
  - d. Neglected Tropical Disease
  - e. Reproductive Health Commodities
  - f. Anti-Tuberculosis Medicines
  - g. Life-Saving Medicines
  - h. HIV Infections and Related Diseases
  - i. In-Vitro Diagnostics (IVDs) for Sars-Cov-2
3. The publication includes the ECOWAS Joint Assessment Procedures and the sample schedules for allopathic drugs.
4. The dossiers format for submission should comply with the ECOWAS Harmonized Common Technical Document (CTD) which could be found on the WAHO website

## Tender Documents

1. [EN - Antimalarial Medicines](#)
2. [EN - Vaccines, Immunoglobulins, Well Characterized Biologics, Bio-Similar and Blood Products](#)
3. [EN - Antibacterial Infections and Related Diseases](#)
4. [EN - Neglected Tropical Disease](#)
5. [EN - Reproductive Health Commodities](#)
6. [EN - Anti-Tuberculosis Medicines](#)
7. [EN - Life-Saving Medicines](#)
8. [EN - HIV Infections and Related Diseases](#)
9. [EN - In-Vitro Diagnostics \(IVDs\) for Sars-Cov-2](#)
10. [FR - Médicaments Antipaludéens](#)
11. [FR - Vaccins, Immunoglobulines, Produits Biologiques Bien Caractérisés, Bio-Similaires et Produits Sanguins](#)
12. [FR - Infections Antibactériennes et Maladies Connexes](#)
13. [FR - Maladies Tropicales Négligées](#)
14. [FR - Médicaments Antituberculeux](#)
15. [FR - Les Médicaments Vitaux](#)
16. [FR - Infections par le VIH et Maladies Connexes](#)
17. [FR - Diagnostics In-Vitro \(DIV\) pour le Sars-Cov-2](#)
18. [FR - Produits de Santé Génésique](#)
19. [EN - Sample Schedule](#)
20. [FR - Sample Schedule](#)
21. [EN - CTD and Annexes](#)
22. [FR - TDC et Annexes](#)
23. [ECOWAS Joint Assessment Procedure](#)

Source: <https://data.wahooas.org/tenders/tenders/list>